Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Sealed dry drug vial
What ifWhat if the vial contained only dry crystalline imatinib mesylate and relied on its seal to keep moisture out?
Claim language“a stabilizing formulation”
A dry filling process meters sterile crystalline imatinib mesylate into a glass vial. A sealed closure limits moisture ingress during storage, and a separately supplied aqueous diluent dissolves the powder immediately before use.
1.2Thin layer for drying
What ifWhat if a thin frozen layer provided a short drying path without a bulking agent?
Claim language“a bulking agent”
The vial rotates during freezing to spread the buffered drug solution over its inner wall. Lyophilization removes ice from the thin layer, and swirling with aqueous diluent dissolves the dried deposit without requiring a freestanding cake.
1.2Single use acidified diluent
What ifWhat if a measured dose of strong acid set the pH without a buffering agent?
Claim language“a buffering agent”
A sealed single-use ampoule contains water for injection acidified with dilute hydrochloric acid. Its fixed fill volume and acid content set the pH after dissolution of the specified drug mass, and the solution is used promptly after mixing.
1.2Feedback controlled ph adjustment
What ifWhat if a pH sensor and metering pumps set the pH during solution preparation without a buffering agent?
Claim language“a buffering agent”
A pH probe measures the mixed solution while metering pumps dispense dilute hydrochloric acid or sodium hydroxide to reach the setpoint. The adjusted solution moves directly to vial filling and freezing, which limits the time spent as an unbuffered bulk liquid.
1.3Near neutral inclusion complex
What ifWhat if a cyclodextrin kept imatinib dissolved at pH 6.5?
Claim language“the pH of the pharmaceutical composition is below 6.0”
Sulfobutyl ether beta-cyclodextrin complexes with dissolved imatinib and raises its apparent aqueous solubility. Equilibrium solubility measurements at pH 6.5 set the cyclodextrin concentration for the target drug concentration and intended dilution.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Reference samples for analytical instrument qualification
An acidic formulation of imatinib, a bulking agent, and a buffering agent is freeze-dried in single-use vials for analytical laboratories. Each vial is reconstituted to a fixed volume with aqueous diluent, and the laboratory records the pH and measures imatinib content by liquid chromatography. The laboratory compares peak area and retention time across replicate vials to assess instrument repeatability.
Component substitution
Glycine as the bulking agent
Glycine replaces the sugar or sugar alcohol as the bulking agent. Imatinib and glycine are dissolved in an aqueous buffer, and the solution pH is adjusted below 6.0 before vial filling and freeze-drying. Glycine contributes solid mass to the dried cake, and the reconstituted solution is checked for pH, clarity, and imatinib recovery.
Parameter or scale variation
Vial fill depth at fixed composition
A single buffered imatinib solution containing a bulking agent at pH 5.2 is dispensed into identical 10 mL vials at fill volumes of 1.0, 2.0, and 4.0 mL. The three groups are loaded on the same freeze-dryer shelf and processed under the same shelf temperature and chamber pressure settings. Product temperature is recorded for each fill volume, and residual moisture and reconstitution time are measured separately for each group.
Combination with existing systems
Reconstitution in a dual chamber syringe
A dual chamber syringe holds the freeze-dried imatinib formulation in the front chamber and a metered aqueous diluent in the rear chamber. Advancing the plunger moves the separating stopper to a bypass that routes the diluent into the front chamber. The diluent volume and buffer concentration are set so the reconstituted solution reaches the intended imatinib concentration at a pH below 6.0.
Automated or data-driven variant
Feedback control of bulk solution ph
A stirred mixing vessel contains dissolved imatinib, the bulking agent, and the buffering agent, with an in-line pH probe installed in a recirculation loop. A controller pulses metering pumps that deliver dilute acid or base and waits for the reading to stabilize after each addition. The controller releases the batch to the vial filler when the pH stays between 5.15 and 5.25 for 60 seconds.
Sensor controlled primary drying endpoint
Vials containing the buffered imatinib formulation and its bulking agent are loaded into a freeze dryer fitted with a thermal conductivity gauge and a capacitance manometer. During primary drying, software tracks the difference between the two pressure readings as water vapor leaves the vials. The controller begins secondary drying when the pressure difference stays below a threshold established with residual moisture measurements for that vial load.
Specific version of a part
Freeze dried imatinib mesylate
Imatinib mesylate dissolves in an acidic aqueous solution containing mannitol and citrate. The solution freezes in the vial, and vacuum drying removes ice and residual water before the vial is sealed.
Mannitol as cake bulking agent
Mannitol supplies dry solids in a citrate-buffered imatinib solution. It crystallizes during a controlled hold in the frozen state and provides a rigid structure after ice sublimes.
Acetate buffer at ph five
Acetic acid and sodium acetate form a buffer at pH 5.0 in a formulation with mannitol as the bulking agent. The acetate pair takes up added acid or base and reduces pH changes during preparation.
Reconstituted solution at ph 5.5
A citric acid and sodium citrate system sets the solution pH to 5.5 after the dried formulation dissolves in a specified volume of water for injection. A calibrated pH electrode measures the resulting solution after complete dissolution.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Preferably, the present invention provides a tablet comprising imatinib mesylate, wherein the tablet provides high polymorphic stability for imatinib mesylate.
A · US 2009/0092669 A1 · ¶ 20
1.2wherein said stabilizing formulation comprises a bulking agent and a buffering agent
A low-pH skin care composition, comprising: a) about 0.1% to 10% of a vitamin B3 compound; b) about 0.1% to 10% of a low-pH buffering system comprising gluconic acid and sodium gluconate; c) about 0.1% to 5% of a polymer thickener comprising at least one of sodium polyacryloyldimethyl taurate and polyacrylate crosspolymer-6; and d) wherein the pH of the composition is between about 2.0 and about 5.0, preferably about 2.5 to about 4.5, and more preferably about 3.5 to 4.3.
B · US 2021/0369589 A1 · ¶ 89
1.3wherein the pH of the pharmaceutical composition is below 6.0.
A low-pH skin care composition, comprising: a) about 0.1% to 10% of a vitamin B3 compound; b) about 0.1% to 10% of a low-pH buffering system comprising gluconic acid and sodium gluconate; c) about 0.1% to 5% of a polymer thickener comprising at least one of sodium polyacryloyldimethyl taurate and polyacrylate crosspolymer-6; and d) wherein the pH of the composition is between about 2.0 and about 5.0, preferably about 2.5 to about 4.5, and more preferably about 3.5 to 4.3.
B · US 2021/0369589 A1 · ¶ 89
An empty cell means only that no passage was reproduced there.
Statements in these documents
The invention relates to formulations containing imatinib with high polymorphic stability.
A · US 2009/0092669 A1 · ¶ 2
It is especially useful in the treatment of various types of cancer, and can also be used for the treatment of atherosclerosis, thrombosis, restenosis, and fibrosis.
A · US 2009/0092669 A1 · ¶ 4
Accordingly, it would be desirable to provide a stable, efficacious, low-pH skin care composition that includes a suitable acid/salt buffer system.
B · US 2021/0369589 A1 · ¶ 4
Surprisingly, it has now been discovered that a low-pH skin care composition that includes a vitamin B3 skin care active, a low-pH tolerant polymeric thickener, and a suitable salt/acid pH buffering system can provide an efficacious skin care product that does not irritate the skin and has better sensory properties than current low-pH skin care products.
B · US 2021/0369589 A1 · ¶ 7
Cite aspatent.fyi, US 2026/0355193 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355193/, SHA-256 1385c9deb0460b9ec8e7d9ca0bf75e3cdf002d48adcc306ce7a7181e514f9fd2